Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetes Care (2018) Vol. 41, Iss. 12, pp. 2669-2701
Open Access | Times Cited: 3144

Showing 26-50 of 3144 citing articles:

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Marc Foretz, Bruno Guigas, Benoı̂t Viollet
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 10, pp. 569-589
Closed Access | Times Cited: 524
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen, et al.
JAMA (2019) Vol. 322, Iss. 12, pp. 1155-1155
Open Access | Times Cited: 516
6. Glycemic Targets: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S97-S110
Open Access | Times Cited: 474
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetologia (2019) Vol. 63, Iss. 2, pp. 221-228
Open Access | Times Cited: 462
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
Derek LeRoith, Geert Jan Biessels, Susan S. Braithwaite, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 104, Iss. 5, pp. 1520-1574
Open Access | Times Cited: 452
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard E. Pratley, Aslam Amod, Søren T. Hoff, et al.
The Lancet (2019) Vol. 394, Iss. 10192, pp. 39-50
Closed Access | Times Cited: 445
Japanese Clinical Practice Guideline for Diabetes 2019
Eiichi Araki, Atsushi Goto, Tatsuya Kondo, et al.
Diabetology International (2020) Vol. 11, Iss. 3, pp. 165-223
Open Access | Times Cited: 442
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Lancet (2021) Vol. 398, Iss. 10300, pp. 583-598
Closed Access | Times Cited: 416
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 3075-3090
Open Access | Times Cited: 405
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
Geltrude Mingrone, Simona Panunzi, Andrea De Gaetano, et al.
The Lancet (2021) Vol. 397, Iss. 10271, pp. 293-304
Closed Access | Times Cited: 404
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 403
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Hyo Shin Yoon, Chung Hwan Cho, Myeong Sik Yun, et al.
Nature Microbiology (2021) Vol. 6, Iss. 5, pp. 563-573
Closed Access | Times Cited: 388
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Type 2 diabetes mellitus in older adults: clinical considerations and management
Srikanth Bellary, Ioannis Kyrou, James E. Brown, et al.
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 9, pp. 534-548
Closed Access | Times Cited: 381
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli, et al.
Molecules (2020) Vol. 25, Iss. 8, pp. 1987-1987
Open Access | Times Cited: 376
Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives
Jasvinder Singh Bhatti, Abhishek Sehrawat, Jayapriya Mishra, et al.
Free Radical Biology and Medicine (2022) Vol. 184, pp. 114-134
Open Access | Times Cited: 358
Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis
Matti Uusitupa, Tauseef Khan, Effie Viguiliouk, et al.
Nutrients (2019) Vol. 11, Iss. 11, pp. 2611-2611
Open Access | Times Cited: 353
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 351
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 329
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani, et al.
Diabetes Care (2019) Vol. 42, Iss. 12, pp. 2272-2281
Open Access | Times Cited: 327
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 317
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Rexiati Ruze, Tiantong Liu, Xi Zou, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 316
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315

Scroll to top